Blueprint Medicines announces proposed public offering of shares of common stock
Blueprint Medicines announced it has commenced an underwritten public offering of $275,000,000 in shares of its common stock. Blueprint Medicines expects to grant underwriters a 30-day option to purchase up to an additional $41,250,000 in shares of its common stock. December 11, 2017